tiprankstipranks
Trending News
More News >

Nxera Pharma Achieves Major Milestones in 2024, Eyes Further Growth

Story Highlights
Nxera Pharma Achieves Major Milestones in 2024, Eyes Further Growth

Confident Investing Starts Here:

Sosei Group ( (JP:4565) ) has shared an update.

Nxera Pharma reported significant achievements in 2024, including the successful launch of PIVLAZ™ and QUVIVIQ™ in Japan, contributing to substantial revenue growth. The company is advancing its clinical pipeline with late-stage trials and forging strategic partnerships, positioning it as a leader in the biopharmaceutical sector. The expansion into South Korea and collaborations with tech companies highlight Nxera’s commitment to innovation and market expansion.

More about Sosei Group

Nxera Pharma is a technology-driven biopharmaceutical company focused on developing and bringing new medicines to patients in Japan and globally. The company operates within the biopharmaceutical industry, with a focus on neurology, neuropsychiatry, metabolic diseases, immunology, and inflammation. Key products include PIVLAZ™ and QUVIVIQ™, and the company is expanding its market presence in Asia.

YTD Price Performance: -1.67%

Average Trading Volume: 614

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $585.8M

See more insights into 4565 stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App